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Abstract Breast cancer is one of the most commonly
diagnosed cancers in women. While there are several effec-
tive therapies for breast cancer and important single gene
prognostic/predictive markers, more than 40,000 women die
from this disease every year. The increasing availability of
large-scale genomic datasets provides opportunities for
identifying factors that influence breast cancer survival in
smaller, well-defined subsets. The purpose of this study was
to investigate the genomic landscape of various breast cancer
subtypes and its potential associations with clinical out-
comes. We used statistical analysis of sequence data gener-
ated by the Cancer Genome Atlas initiative including somatic
mutation load (SML) analysis, Kaplan–Meier survival
curves, gene mutational frequency, and mutational enrich-
ment evaluation to study the genomic landscape of breast
cancer. We show that ER?, but not ER-, tumors with high
SML associate with poor overall survival (HR = 2.02).
Further, these high mutation load tumors are enriched for
coincident mutations in both DNA damage repair and ER
signature genes. While it is known that somatic mutations in
specific genes affect breast cancer survival, this study is the
first to identify that SML may constitute an important global
signature for a subset of ER? tumors prone to high mortality.
Moreover, although somatic mutations in individual DNA
damage genes affect clinical outcome, our results indicate
that coincident mutations in DNA damage response and
signature ER genes may prove more informative for ER?
breast cancer survival. Next generation sequencing may
prove an essential tool for identifying pathways underlying
poor outcomes and for tailoring therapeutic strategies.
Keywords Mutation load  Breast cancer  DNA damage
repair  Estrogen receptor
Abbreviations
BER Base excision repair
DDR DNA damage response
ER Estrogen receptor
HML High mutation load
HR Homologous recombination
LML Low mutation load
MMR Mismatch repair
NER Nucleotide excision repair
NHEJ Non-homologous end joining
PR Progesterone receptor
SML Somatic mutation load
TCGA The Cancer Genome Atlas
Introduction
Breast cancer is the second leading cause of cancer-related
death in women [1]. Comprehensive gene expression
analyses of breast cancer confirmed the presence of the
following three histopathologically identified subsets: (1)
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estrogen receptor (ER)-positive, progesterone receptor
(PR)-positive; (2) human epidermal growth factor receptor
2 (HER2)-enriched; and (3) triple-negative (lacking ER,
PR, and HER2) [2]. ER? breast cancers account for
approximately 70 % of breast tumors diagnosed, and while
effective targeted endocrine therapies have been identified,
*25 % of these tumors develop resistance over time and
consequently undergo relapse [3]. Analysis of aromatase
inhibitor-treated ER? breast tumors using whole exome
sequencing identified associations between endocrine
resistance and mutations in ER-related genes, including
GATA3, CBFB, TBX3, RUNX1, and PIK3CA [4]. Similarly,
loss of PR in ER? breast tumors associates with loss of
estrogen-dependence, increased endocrine resistance, and
diminished overall survival [5]. The discovery of under-
lying targetable pathways of resistance in this subgroup is
required for the identification of markers and the devel-
opment of tailored therapeutic strategies.
Several prognostic markers have been identified for breast
cancer including lymph node involvement, tumor stage,
TP53 status, PAM-50 subtype, ER status, PR status, and
HER2-enrichment. Mutations in DNA damage response
(DDR) pathways are also implicated in clinical outcome of
breast cancer. Mutations in BRCA1 (a double-strand break
(DSB) repair gene) and TP53 (a DDR checkpoint gene), for
instance, are associated with triple-negative breast cancer
and poor clinical outcome [6, 7]. Mutations in other DDR
genes including ATM, ATR, and BRCA2 (all DSB repair
genes) have been associated with increased susceptibility to
breast cancer [8]. While some of these markers have con-
tributed significantly to the tailoring of therapeutic strate-
gies, they do not comprehensively predict resistance or
increased mortality. Moreover, despite much effort no fur-
ther globally significant single genes have been identified as
predictors of breast cancer clinical outcome, and it is unli-
kely that many such genes remain to be discovered. In non-
breast cancers, DNA damage affects tumor somatic mutation
load (SML), and mutations in DDR genes can be predictive
of clinical outcomes, such as overall and relapse-free sur-
vival [9, 10]. In this context, we postulate that genome-wide
phenotypic signatures might have a wide impact on breast
cancer prognosis and prediction.
In support of this idea, increased genomic instability in
tumors has been associated with the basal-like tumor sub-
type [11] and with metastasis-free survival in lymph node-
negative luminal breast tumors although this analysis was
limited by its sample size [12]. This genomic instability
score was found to be highly associated with TP53 muta-
tions and proliferative indices. However, genomic insta-
bility in this group was restricted to a very small number of
tumors, indicating a potential limitation of its scope for use
as a prognostic/predictive marker. Recent whole exome
sequencing of colorectal cancer by the TCGA initiative
identified a high SML subset associated with microsatellite
instability, mutations in mismatch repair (MMR) pathway
genes, and favorable outcome [13]. However, the effects of
SML on breast cancer have not yet been elucidated and we
postulated that, as in colorectal cancer, SML of a breast
tumor would influence patient survival. To test this
hypothesis, we analyzed whole exome sequencing data
recently generated by the The Cancer Genome Atlas
(TCGA) initiative from breast tumors [14].
Materials and methods
Informatics
Whole exome somatic variants, gene expression, clinical,
and epidemiological data were downloaded from The Can-
cer Genome Atlas Breast Invasive Carcinoma data portal
(https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?di
seaseType=BRCA&diseaseName=Breast%20invasive%20
carcinoma). Details of sample acquisition, DNA sequenc-
ing, and RNA expression analyses have been described in
the original TCGA publication [14]. Data processing and
statistical analysis were carried out using the R statistical
software suite [15] and custom scripts written in Perl.
Statistics
t tests were used to determine p-values for continuous data,
with Holm’s adjustment for multiple comparisons as
required. For data with non-normal distribution, the Wil-
coxon Rank Sum test was used. Fisher’s exact tests were
used to determine significance of categorical data. Survival
analyses used log-rank tests, and Kaplan–Meier curves
were plotted using R. Due to the low median follow-up
time of the TCGA cohort (575 days), all survival analyses
extend only 10 years. Proportional hazards were calculated
using the Cox regression model, and the coxph function in
R was used to confirm that the dataset met the assumptions
for the Cox regression analysis.
Clinical information
ER status provided in the publically available TCGA
dataset was used to sort the tumors into ER? and ER-
groups. Age at diagnosis of [50 years was used as a sur-
rogate indicator of postmenopausal status.
Gene lists
Lists of genes within the specific DNA damage response,
MAPK, NFkB, and T-cell marker pathways were generated
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using the KEGG database (keywords: DNA damage repair;
base excision repair (BER); nucleotide excision repair
(NER); MMR; homologous recombination (HR); non-
homologous end joining (NHEJ); DDR checkpoint; MAPK
signaling; NFkB signaling; T-cell marker) (see Tables 1,
2). Genes with known prognoses [4, 16–18] were generated
from the previous literature (see Table 5). A consensus
ER? breast cancer signature gene list (ABCA3, ACADSB,
ALDH3B2, AR, ANXA9, BCL2, CA12, CCND1, CGA,
DNAJC12, ESR1, ERBB4, FOXA1, GATA3, GJA1,
GREB1, HPN, IGFBP4, IL6ST, KRT18, LRBA, MYB,
NAT1, NRIP1, PGR, PTPRT, RABEP1, RARRES1, RERG,
RET, SEMA3B1, SLC27A2, SLC39A6, SULT2B1, TFF1,
TFF3, XBP1) was generated from five independent studies
profiling ER? (luminal) breast tumors and cell lines
[19–23].
Results
Mutation load distribution is different between ER?
and ER- breast cancer
Our sample set comprises 762 invasive breast tumors from
the TCGA dataset. Immunohistochemical analysis shows
that the majority of these tumors (73.4 %) are ER?
(Table 3). The mean SML is 67.23 mutations per tumor
(Table 3); however, ER- tumors have a significantly
higher SML than ER? tumors (p \ 0.0001; Fig. 1a). Fur-
thermore, ER? and ER- tumors are characterized by
marked differences in SML distribution. ER? tumors have
a median SML of 46 (Fig. 1a) and a mean SML of 62.7,
with a small subset of these tumors carrying significantly
high mutation loads (HMLs) (Fig. 1a). Conversely, ER-
tumors lack a distinct high mutation subset, instead almost
half (42 %) of the tumors carry mutation loads higher than
the mean SML (Fig. 1a).
SML associates with ER? breast cancer survival
Associations have been found between genomic instability,
mutations in specific DNA damage genes, and clinical
outcome in various cancers, including the breast [8], but
there have been few previous reports on the effect of
mutation load on any type of cancer. One report identified
an association between high SML and good clinical out-
come in colorectal cancer [13]; however, there are no such
associative findings reported for breast cancer. To test
whether mutation load affected survival in breast cancer,
we divided all breast cancers into HML and low mutation
load (LML) groups based on the mean SML across all
breast cancers. We found that SML had no effect on breast
cancer survival when all tumors were considered (Fig. 1b)
in accord with the previous TCGA report [14]. However,
we postulated that SML might differentially affect breast
cancer outcomes based on ER status, as suggested by the
distinct distribution of SML between ER? and ER- breast
tumors (Fig. 1a). Therefore, we next analyzed the effect of
SML on overall survival independently in the ER? and
ER- subsets of breast cancer by defining tumors as LML or
HML based on mean SML for each ER subtype. We found
that patients with ER? HML tumors exhibit significantly
shorter overall survival than do patients with ER? LML
tumors (p = 0.02, Fig. 1c), and conversely, overall sur-
vival is not affected by SML in patients with ER- tumors
(p = 0.25, Fig. 1d). In addition, the overall survival curve
of ER? HML tumors is virtually identical to the survival
curve of ER- tumors (Fig. 1e), emphasizing the signifi-
cantly poor overall survival observed in the HML subset of
ER? breast tumors. For most of the remaining analyses, we
focused on the effects of mutation load on ER? breast
cancer.
We next used a Cox regression model that assessed effect
of SML on survival in the presence of known prognostic/
predictive factors including PR status, HER2 enrichment,
tumor stage, and lymph node involvement. Our results
showed that mutation load was an independent prognostic
factor in ER? tumors (p = 0.04, Table 4) with a hazard
ratio (HR = 2.02) higher than that of all other factors
considered except nodal status. In fact PR status no longer
contributed significantly to survival (p = 0.15) although
lymph node status remained significant in the multivariate
analysis (p = 0.02). The fact that tumor stage did not affect
clinical outcome significantly in the Cox analysis is likely
due to the small number of patients and the short follow-up
time in this study (see ‘‘Materials and methods’’ section).
The HML subset overall was enriched for HER2? tumors
(36/395 LML tumors were HER2? vs 36/105 HML tumors;
p \ 0.001), and the average SML of HER2-enriched tumors
(79.5 ± 55.9) was higher than HER2-negative tumors
(65.6 ± 53.5; p = 0.02). However, HER2 enrichment did
not contribute significantly to overall survival (Table 4)
indicating that HML may be a more compelling contributor
to survival in ER? breast cancer than HER2 status.
DNA damage repair pathways are mutated in tumors
with HML
To investigate the pathways underlying the HML pheno-
type, we next investigated whether HML associated with
inactivation of DDR pathways by assessing the mutational
status of genes from the DDR checkpoint, as well as from
each of the five major DDR pathways: BER; NER; MMR;
HR; and NHEJ (see ‘‘Materials and methods’’ section and
Table 2). We analyzed the proportion of tumors with
mutations in at least one gene from each pathway in HMLs
Breast Cancer Res Treat (2014) 146:211–220 213
123
vs LMLs, and the mutational frequency (i.e., the number of
non-silent mutations in genes of a specific pathway over
total number of mutations in all genes) (Fig. 2a, b).
Mutational analysis in this study is confounded by the
fact that HML tumors are theoretically more likely to
mutate any given gene than LML tumors. To account for
this bias, we calculated baseline statistics of (1) the pro-
portion of tumors with mutations in any given gene and (2)
the frequency of mutations in any given gene for both HML
and LML subset tumors. We found that the baseline pro-
portion of tumors that have a mutation in any gene is 2.5-
fold higher in the HMLs relative to the LMLs as would be
expected of tumors with significantly higher mutation load
(Fig. 2c, inset). However, we found that the baseline
mutational frequency of any gene was similar between the
HMLs and LMLs suggesting that the likelihood of any
random gene being mutated was comparable between the
HML and LML subsets (Fig. 2d, inset). An independent
calculation of these same baseline parameters on genes
from three randomly selected KEGG-generated pathways
Table 1 KEGG-generated list of genes from three cancer-related
pathways
Gene name Pathway
FOS, JUN, MAP2K3, MAP2K4, MAPK8, MAPK8I-
3, MAP3K1, MAP3K7, TNF, MAPK3, MAPK6,
MAPK12, MAPK13, MAPK14, MAPK9, MST1,
MAP4K1, MAP2K7, MAP2K2, MAP2K6,
MAP3K4
MAPK
CASP8, CHUK, IKBKB, IL1B, MAP4K4, NFKB1,
NFKB2, NFRKB, REL, IRAK1
NFkB
CD4, CREBBP, CTLA4, FASLG, IL15, JAK2,
LAG3, MAPK8, TGFB3, TNFRSF8, TNFRSF9,
TYK2, CD27, CD40LG, CD80, PTPRC, CCR5,
CXCR3, IL12B, IL12RB2, IL18R1, IL1RL1, IL27,
IL7R, STAT1, STAT4, TBX21, TLR4, CCL11,
CCL5, CCL7, CCR4, GATA3, GF1I, ICOS,
IL13RA1, IL1R1, IL25, IRF4, JAK1, MAF,
NFATC1, NFATC2, PCGF2
T-cell
regulation
Table 2 KEGG-generated list of DNA damage repair genes
Base excision repair (BER) DDR pathway
APEX1, APEX2, CCNO, FEN1, LIG3,
MBD4, MPG, MUTYH, NEIL1, NEIL2,
NEIL3, PARP1, PARP2, PARP3, PCNA,
POLB, SMUG1, TDG, UNG, XRCC1
Base excision repair
(BER)
ATXN3, CCNH, DDB1, DDB2, ERCC1,
ERCC2, ERCC3, ERCC4, ERCC5,
ERCC6, ERCC8, MMS19, PNKP, POLL,
RAD23A, RAD23B, RPA1, RPA3, SLK,
XAB2, XPA, XPC
Nucleotide excision
repair (NER)
MLH1, MLH3, MSH2, MSH3, MSH4,
MSH5, MSH6, PMS1, PMS2, POLD3,
TREX1
Mismatch repair
(MMR)
ATM, BLM, BRCA2, DMC1, H2AFX,
MUS81, POLD1, RAD51, RAD51C,
RAD52, RAD54B, RAD54L, RPA2,
TP53BP1
Homologous
recombination (HR)
DLCRE1C, DNTT, LIG4, MRE11A, NBN,
POLM, PRKDC, RAD50, XRCC2,
XRCC5, XRCC6
Non-homologous end
joining (NHEJ)
ABL1, ATR, BRIP1, CEP63, CHEK1,
CHEK2, CHKA, CLSPN, DBF4, E2F1,
FOXN3, GRP, HUS1B, MAD2L2,
MAPK14, MYH1, PDP1, PIN4,
PNPN11, RAD1, RFC4, TIPIN, TP53,
WEE1, ZAK
DDR checkpoint
ATRIP, ATRX, BARD1, BAX, BBC3,
BRCA1, CDC25A, CDC25C, CDK7,
CDKN1A, CIB1, CRY1, CSNK2A2,
DDIT3, EXO1, FANCA, FANCD2,
FANCG, GADD45A, GADD45G, LIG1,
MAPK12, MCPH1, MDC1, MGMT,
NTHL1, OGG1, PPM1D, PP1R15A,
RAD17, RAD18, RAD21, RAD51B,
RAD9A, RBBP8, REV1, RFC1,
RNF168, RNF8, SIRT1, SMC1A,
SUMO1, TOP3A, TOPSBP1, TP73,
XRCC3, XRCC6BP1
Multiple (Other)
Table 3 Descriptive characteristics of TCGA dataset used in the
study
Characteristic Mean Standard deviation
Age at diagnosis (years) 57.97 13.15
Mean mutation count (n) 67.23 52.79
Mean overall survival (days) 901.53 1069.441
Total number (n) 762
Tumor size at diagnosis (n)
T1 201
T2 441
T3? 109
Unknown 11
Nodal involvement at diagnosis (n)
N0 364
N1 249
N2? 138
Unknown 11
ER status of tumor (n)
ER-positive 559
ER-negative 165
Triple-negative 116
Unknown 38
HER2 status of tumor (n)
HER2-positive 105
HER2-negative 621
Unknown 36
Vital status of patient (n)
Alive 671
Deceased 91
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revealed no significant increase in mutational proportion or
frequency in HMLs (Fig. 2e, f), indicating that high muta-
tion load does not necessarily enrich for mutations in every
pathway. Based on these analyses, we set the threshold to
find mutational enrichment in the HML subset as twice the
baseline difference between HMLs and LMLs. This means
that in order to find mutational enrichment in DDR genes in
HMLs, 5-fold more tumors would need to have these genes
mutated at 2-fold higher frequencies than LMLs.
Using these conservative thresholds, we found no sig-
nificant enrichment for DDR mutations overall in HMLs
over LMLs (Fig. 2a, b). However, mutations in MMR
pathway genes occurred in 16-fold more tumors and
occurred at 7-fold higher frequency in HML than in LML
ER? tumors indicating significant enrichment over and
above our set thresholds (Fig. 2a, b). Uniquely, every gene
specific to the MMR pathway was mutated at least once in
the HML subset of ER? tumors (Fig. 3a). Genes from the
single-strand break repair pathway, NER, were also
mutated in 7-fold more HML tumors and at 2.5-fold higher
frequency relative to the LML ER? tumors (Fig. 3a).
Notably, there was no significant enrichment in the HMLs
in DNA damage checkpoint genes (Fig. 2a, b). Some genes
from the double-strand break repair pathways, e.g., BLM
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and XRCC4, are mutated at higher frequencies and in more
tumors in the HML subset than in the LML subset, but this
enrichment is not significant (Figs. 3b; 2a, b).
In addition, we found a 50 % increase in mean SML in
ER? HML tumors with mutations in DDR pathway genes,
while mutations in DDR checkpoint genes did not affect
SML (Fig. 3c). Especially striking is the observation that
mutations in TP53 occur in a significant fraction of breast
tumors and were previously reported to affect genomic
instability [11] but are not enriched over the set threshold
in the HML group (0.96-fold for mutational frequency and
2.97-fold for tumor proportion) relative to the LML group.
While mutations in DDR genes resulted in increased
mutation load within LML subset tumors (Fig. 3c), the
extremely small effect size limits the biological relevance
of this finding. Together, these results indicate that the
HML subset of ER? tumors is associated with mutations in
DDR pathway genes, specifically in MMR and NER genes,
but not with mutations in DDR checkpoint and double-
strand break repair genes.
Mutations in known prognostic genes do not affect
survival
Next, we investigated potential pathways underlying the
poor survival phenotype associated with HML tumors
using a candidate approach. To determine whether the
HML subset of ER? tumors is enriched for mutations
associated with poor prognosis, we generated a list of
known prognostic genes mutated at [10 % frequency in
human breast cancer based on the existing literature [4, 16–
18] (see ‘‘Materials and methods’’ section and Table 5).
We assessed the proportion of tumors with mutations in
these genes in both the HML and LML ER? subsets. Our
results demonstrate that the LML subset has a significantly
higher proportion of good prognostic mutations than poor
prognostic mutations (p = 0.002), (Fig. 4a). However,
there were no significant associations found between these
known prognostic mutations and overall survival in either
HML or LML subsets (Fig. 4b). These data indicate that
mechanisms other than those associated with known
prognostic genetic mutations mediate the association
between SML and breast cancer survival.
Coincident mutations in ER and DDR genes are
enriched in HML breast tumors and associate with poor
patient survival
We next hypothesized that inactivation of DDR increases the
frequency of genetic mutations in ER pathways thereby
decreasing dependence on ER signaling and potentially
increasing resistance to therapy. To test this hypothesis, we
assessed the mutational frequency of ER signature genes in
HML and LML tumors (see ‘‘Materials and methods’’ sec-
tion), and the correlation between mutations in ER signature,
DDR checkpoint, and DDR pathway genes. Mutations in ER
signature and DDR checkpoint genes occurred at compara-
ble rates between LML and HML tumors, both singly and in
combination (p [ 0.9; Fig 4c). However, when we com-
pared tumors with coincident mutations in DDR pathway
and ER signature genes, we observed significant enrichment
in the HML subset tumors (*20 %) compared to LML
subset tumors (\10 %; p = 0.03; Fig. 4c).
We next evaluated the clinical outcome of women with
tumors having mutations in both DDR and ER genes. As
predicted by our hypothesis, HML tumors with mutations
in both DDR pathway and ER signature genes associate
with worse overall survival than all other HML tumors
(p = 0.007, data not shown). Notably, even LML tumors
with mutations in genes of both the DDR and ER pathways
associate with significantly worse overall survival than all
other LML tumors (p = 0.01; Fig 4d). Further, ER?
tumors with coincident mutations in DDR pathway and ER
signature genes (*10 % of all ER? tumors) associate with
significantly worse overall survival than all other ER?
tumors independent of mutation load (p = 0.0008; Fig. 4f),
unlike ER- tumors (Fig. 4e). These data indicate that
coincident mutations in DDR and ER signature genes could
constitute an indicator of poor prognosis in ER? breast
tumors.
Table 4 Proportional hazards table identifying mutation load as an
independent prognostic factor for ER? breast cancer
Factor Hazard Ratio CI p-Value
Mutation load
LML Ref.
HML 2.02 1.02–4.00 0.04
HER2 status
Negative Ref.
Positive 1.65 0.66–4.12 0.29
PR status
Negative Ref.
Positive 0.55 0.25–1.24 0.15
Tumor stage
Stage I Ref.
Stage II 1.11 0.34–3.65 0.86
Stage III? 0.38 0.05–2.57 0.32
Nodal involvement
N0 Ref.
N1 1.81 0.75–4.35 0.32
N21 8.35 1.43–48.68 0.02
The bolding just highlights the factors that significantly affect breast
cancer survival
* p-Value generated by Cox Regression Analysis for Proportional
Hazards
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Discussion
Mutation load and cancer outcome association in breast
cancer is unique
The results presented here indicate that in ER? breast cancer
high SML may contribute to poor breast cancer survival,
contrary to previous reports in colorectal cancer. Our results
suggest the hypothesis that ER? tumors with mutations in
both DDR and ER signature genes are inherently less
dependent on ER signaling than ER-driven tumors. This
hypothesis may also explain the dichotomous behavior
between ER? and ER- breast tumors with respect to
mutation load. Therefore, tumors characterized by coinci-
dent mutations in DDR and ER genes may be resistant to
current therapies, especially anti-estrogen-based therapies.
To advance this field it will be necessary to reinvestigate the
effects of mutation load on ER- breast cancer as both the
number of sequenced tumors as well as the length of patient
follow-up in the TCGA sample set increases.
MMR gene mutations affect breast cancer survival
Large-scale studies like the TCGA have reported few new
genes that have global impact on breast cancer prognosis or
prediction. New discoveries will, therefore, most likely
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and from the previous literature and are reproduced in Tables 1 and 2
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arise through pathway level, rather than gene level, anal-
yses. In alignment with this idea, the HML subset of ER?
tumors described here is enriched for somatic mutations in
MMR pathways, rather than individual genes.
While deleterious mutations in MMR genes have been
identified in primary breast tumors as well as in adjacent
neoplastic tissue [24, 25], we describe here a correlation
between MMR genetic mutations and poor clinical out-
come of patients with ER? breast tumors. In contrast to our
results, a recent publication analyzing mutational signa-
tures of various cancers was unable to identify any corre-
lation between MMR deficiency and mutational signature
in breast cancer [26]. This discrepancy likely arose because
this prior analysis examined all breast cancers as a single
group instead of considering ER? and ER- breast cancer
individually. This highlights the importance of incorpo-
rating knowledge of tumor biology into analyses rather
than relying on pure analytics alone.
Clinical significance of mutation load and sequencing
strategies in breast cancer
Our results identify mutation load as a quantitative geno-
mic phenotype, rather than a genotype, associated with
clinical outcome. Using mutation load for prediction/
prognosis enables easy, quantitative estimation, and may
have a greater global impact on breast cancer clinical
outcomes than many single genes which are currently
considered important. Moreover, mutation load may be
indicative of the increased potential of an ER? breast
tumor to quickly become resistant to endocrine therapy by
mutating individual pathways that can be discovered
C
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ns
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100
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250
LML HML
DDRmut/Chkpt NL
DDRNL/Chkpt NL
DDRNL/Chkpt mut
p<0.001
p=0.01
Fig. 3 ER? HML tumors are enriched for mutations in MMR and
NER pathway genes. a, b Venn diagrams indicating genes from the
specified DDR pathway that are mutated in either the HML (red) or
LML (blue) subset of ER? tumors, in both (purple) and in neither
(white). Increasing font size indicates an increasing proportion of
tumors with mutations in the specific gene. c Bar graph depicting the
average SML in tumors with specified mutational status. Student’s
t test with Holm’s adjustment for multiple comparisons was used to
define p-values. Chkpt, genes from the DNA damage checkpoint; NL,
tumors with no identified mutations in genes from the specified
pathway; mut, tumors with identified non-silent mutations in genes
from the specified pathway; ns not significant
Table 5 List of ER signature genes with prognostic mutational status
in breast cancer
Gene
name
Mutational
prognosis
Reference
GATA3 Good Ellis et al. [4] Nature
MAP3K1 Good Ellis et al. [4] Nature
MAP2K4 Good Ellis et al. [4] Nature
PIK3CA Good Cizkova et al. [16] Br Canc Res
CDKN1B Poor Depowski et al. [17] Mod Pathol
RB1 Poor Ellis et al. [4] Nature
PTEN Poor Alkarain et al. [18] J Mamm Gl Neopl
TP53 Poor Ellis et al. [4] Nature
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through mutational analysis. Therefore, our discovery that
high SML may serve as a marker for poor survival in a
subset of breast tumors indicates that genome wide
sequencing can offer important clinically relevant infor-
mation for ER? breast cancer.
Conclusions
Our data indicate a novel association between SML and
clinical outcome in breast cancer. Our data also implicate
somatic mutations in DDR pathway genes and in ER-
related genes as predictive of poor clinical outcome for
ER? breast cancer. It is important to acknowledge the
small number of samples and the short follow-up time in
this dataset which warrant a larger study to ascertain the
contribution of mutation load to clinical outcome. How-
ever, approximately one-third of the ER? tumors used in
this study were characterized as HML ([65 mutations).
This indicates that a significant proportion of ER? breast
cancer patients could benefit from SML characterization of
their tumors. As the cost of DNA sequencing steadily
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Fig. 4 Coincident mutations in
DDR and ER signature genes
associate with poor survival
irrespective of mutation load.
a Percentage of tumors with
mutations in genes associated
with either good or poor
prognosis in specified subsets.
Fisher’s exact test was used to
determine the p-value.
b Kaplan–Meier survival curves
of indicated groups. Log-rank
test was used to generate p-
values. c Bar graph depicting
the percentage of tumors with
mutations in the specified
pathways. Fisher’s exact test
was used to identify p-values.
The list of ER signature genes is
presented in ‘‘Materials and
methods’’ section. d–f Kaplan–
Meier survival curves of
indicated groups. Log-rank test
was used to determine p-values.
ER, ER signature genes; DDR,
genes from the five major DNA
damage response pathways;
Chkpt, genes from the DNA
damage checkpoint; mut,
tumors with non-silent
mutations in genes from the
specified pathway; NL, tumors
with no identified mutations in
genes from the specified
pathway; ns, not significant
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decreases [27], analysis of SML could become a reasonable
and useful prognostic marker to help select patients with
aggressive and/or endocrine-resistant ER? tumors, who
may benefit from aggressive therapy targeting non-hor-
monal pathways.
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